Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the approval of the COVID-19 vaccine for children aged 5 to 11 years and conversations with parents.
The authorization of the Pfizer/BioNTech COVID-19 vaccine in children aged 5 to 11 years has been met with positive reactions from pediatricians and many parents. As the rollout to the age group starts, allaying safety fears and knowing who to turn to for the vaccine are key. The editor-in-chief of Contemporary Pediatrics, Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sat down with the editorial team to answer some common questions.
CDC recommends nirsevimab be prioritized for highest-risk infants amid limited availability
October 26th 2023The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
Navigating a complex case of pediatric COVID-19 with immunomodulatory therapies
October 21st 2023Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.